GKOS Stock: 32% Revenue Jump in 2025 - Hold or Fold?

Glaukos has quietly built an empire in micro‑invasive glaucoma surgery, pioneering tiny implants and earning strong surgeon loyalty through years of innovation. The company ($GKOS) has pushed into drug delivery with iDose TR and into corneal therapy with Epioxa, sparking a major revenue surge and forcing management to pour money into launches and marketing. That strategy has produced exciting growth but also widening losses and a big non‑cash impairment that clouded GAAP results, leaving profitability still out of reach. It’s a classic high‑risk, high‑reward story—strong patents and a clean balance sheet on one side, uncertain path to profits on the other—can these new products turn momentum into lasting earnings?This podcast is for informational and educational purposes only. Information may not be complete or accurate. It does not constitute financial, investment, legal, or other professional advice. Always do your own research and consult with a licensed financial advisor.And don't forget, you can suggest the tickers you're interested in at www.the5minuteticker.com.